Australia markets closed

Petros Pharmaceuticals, Inc. (PTPI)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.5190-0.0952 (-15.50%)
At close: 04:00PM EDT
0.5301 +0.01 (+2.14%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6142
Open0.6143
Bid0.4773 x 100
Ask0.5277 x 100
Day's range0.4667 - 0.6500
52-week range0.4667 - 4.7400
Volume600,790
Avg. volume499,703
Market cap3.633M
Beta (5Y monthly)2.45
PE ratio (TTM)N/A
EPS (TTM)-7.3800
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.00
  • GlobeNewswire

    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals

    Lemonaid Health will offer customers more affordable access to fast-acting branded ED medication that works as quickly as 15 minutes prior to sexual activitySUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Lemonaid Health, Inc., a subsidiary of 23andMe Holding Co., (Nasdaq: ME), and a leading telemedicine provider, is now offering Petros Pharmaceuticals, Inc.’s (Nasdaq: PTPI), prescription erectile dysfunction (ED) medication STENDRAⓇ (avanafil) through its telehealth platform. Working direct